dc.contributor.author | Krol, I | |
dc.contributor.author | Castro-Giner, F | |
dc.contributor.author | Maurer, M | |
dc.contributor.author | Gkountela, S | |
dc.contributor.author | Szczerba, BM | |
dc.contributor.author | Scherrer, R | |
dc.contributor.author | Coleman, N | |
dc.contributor.author | Carreira, S | |
dc.contributor.author | Bachmann, F | |
dc.contributor.author | Anderson, S | |
dc.contributor.author | Engelhardt, M | |
dc.contributor.author | Lane, H | |
dc.contributor.author | Evans, TRJ | |
dc.contributor.author | Plummer, R | |
dc.contributor.author | Kristeleit, R | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | Aceto, N | |
dc.date.accessioned | 2018-11-14T09:45:05Z | |
dc.date.issued | 2018-08-14 | |
dc.identifier.citation | British journal of cancer, 2018, 119 (4), pp. 487 - 491 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2931 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/s41416-018-0186-7 | |
dc.description.abstract | Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular CTC clusters are generated in this disease and whether they can bypass the physical hurdle of the blood-brain barrier. Here, we assessed CTC presence and composition at multiple time points in 13 patients with progressing GBM during an open-label phase 1/2a study with the microtubule inhibitor BAL101553. We observe CTC clusters ranging from 2 to 23 cells and present at multiple sampling time points in a GBM patient with pleomorphism and extensive necrosis, throughout disease progression. Exome sequencing of GBM CTC clusters highlights variants in 58 cancer-associated genes including ATM, PMS2, POLE, APC, XPO1, TFRC, JAK2, ERBB4 and ALK. Together, our findings represent the first evidence of the presence of CTC clusters in GBM. | |
dc.format | Print-Electronic | |
dc.format.extent | 487 - 491 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Glioblastoma | |
dc.subject | Brain Neoplasms | |
dc.subject | Disease Progression | |
dc.subject | Oxadiazoles | |
dc.subject | Benzimidazoles | |
dc.subject | Cell Count | |
dc.subject | Cluster Analysis | |
dc.subject | Xenograft Model Antitumor Assays | |
dc.subject | Mutation | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Gene Regulatory Networks | |
dc.subject | Neoplastic Cells, Circulating | |
dc.subject | Genetic Variation | |
dc.subject | Whole Exome Sequencing | |
dc.title | Detection of circulating tumour cell clusters in human glioblastoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-06-25 | |
rioxxterms.versionofrecord | 10.1038/s41416-018-0186-7 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 4 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Addictions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Molecular Addictions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 119 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (de Bono Prostate) | |
icr.researchteam | Molecular Addictions | |
icr.researchteam | Cancer Biomarkers | |
dc.contributor.icrauthor | Coleman, Niamh | |
dc.contributor.icrauthor | Carreira, Suzanne | |